

20. **REMARKS**

Claim 6 has been amended to provide proper antecedent basis.

Claim 7 has been amended to provide proper antecedent basis.

Claim 13 has been amended to remove the phrase “including tumor angiogenesis”, and

Claim 19 has been added to provide species coverage of the genus claimed in Claim 13, to more particularly point out an aspect of the present invention.

Rejection under 35 U.S.C. § 112, first and second paragraph

Reconsideration and withdrawal of rejection of claims 6, 7, and 13 under 35 U.S.C. § 112 is requested.


On page two of the Office Action, the Examiner rejected claims 6, 7, and 13 under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Applicants respectfully request withdrawal of the rejection for the following reasons:

- I. Claims 6 and 7 have been amended to reflect dependency on compound claims 5 and 6, respectively.
- II. Claim 13 has been amended to read “angiogenesis”, and new dependant claim 19 has been added to include “tumor angiogenesis.”

In view of the foregoing amendments, it is respectfully submitted that all claims now active in the present application are in condition for allowance. Therefore, passage of the application and claims to issue is respectfully requested.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Rachel A. Polster".

Rachel A. Polster


Registration No. 47,004

Telephone: 314-274-7354

Pharmacia Corp. Patent Dept.

P.O. Box 1027

Chesterfield, MO 63006



PATENT

Case SO-291 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Vianello et al.

GROUP ART UNIT: 1624

SERIAL NUMBER: 09/924,709

EXAMINER: Richard L. Raymond

FILED: August 8, 2001

DATE: March 6, 2003

TITLE: NOVEL SUBSTITUTED BENZOXAZINES AS INTEGRIN ANTAGONISTS

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
First Class Mail in an envelope addressed to:
Commissioner of Patents and Trademarks,
Washington D.C., 20231 on March 6, 2003

Linda Haley

Linda Haley Date: March 6, 2003


RECEIVED
MAR 18 2003
TECH CENTER 1600/2900

APPENDIX TO AMENDMENT



Version of Claims with Markings to Show Changes Made





6. (Once amended) A pharmaceutical composition of claim [2] 5 wherein :

G is selected from the group consisting of



wherein Q is NH or O and Q' is selected from the group consisting of H, C₁-C₆ alkyl, phenyl, and phenyl-C₁-C₄-alkyl;







B is $(\text{CH}_2)_q$ where q is 2,3,4;

R₂ is a phenyl or pyridine ring unsubstituted or optionally substituted by one to three substituents independently selected from the group consisting of H, C₁-C₄ alkyl, C₁-C₄ alkoxy, OH, halogen, CF₃.

7. (Once amended) A pharmaceutical composition of claim [3] 6 wherein :

G is selected from the group consisting of



13. (Once amended) The method according to claim 9, wherein the condition treated is bone resorption, osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, neoplasia (solid tumor growth), angiogenesis [including tumor angiogenesis], diabetic retinopathy, arthritis, psoriasis and periodontal disease, or smooth muscle cell migration including restenosis.

19. (New) The method according to claim 9, wherein the condition treated is tumor angiogenesis.